Last Update 01 Apr 26

Fair value Decreased 2.39%

OSCR: Enrollment Resilience And 2026 Profit Outlook Will Drive Future Earnings Power

Narrative Update on Oscar Health

The analyst price target for Oscar Health has shifted modestly, with the revised fair value moving from about $15.78 to $15.40 as analysts factor in updated views on revenue growth, profit margins, and a lower forward P/E multiple alongside recent rating changes and price target adjustments.

Analyst Commentary

Recent Street research around Oscar Health reflects a mix of optimism and caution, with price target resets and rating changes feeding into the modestly reduced fair value estimate.

Bullish Takeaways

Bullish analysts highlight the recent upgrade in rating as a sign that execution on the core business is tracking better than earlier expectations, which supports the current valuation despite a slightly lower fair value estimate.
The move from a Sell to Neutral stance, along with a price target shift to US$17 from US$12, signals greater confidence in Oscar Health's ability to sustain exchange enrollment, even with the expiration of enhanced subsidies.
Some bullish analysts point to improved comfort with the earnings and revenue outlook, which they see as better aligned with the stock's current P/E and forward expectations.
Positive commentary around enrollment holding up better than feared suggests that growth assumptions built into current models may be less at risk than previously thought.

Bearish Takeaways

Bearish analysts have trimmed price targets, including a US$2 reduction from one firm, reflecting a more conservative stance on valuation and embedding a lower forward P/E multiple.
The shift to viewing the shares as fairly priced indicates limited perceived upside at current levels, which could cap enthusiasm even with rating upgrades.
There is ongoing caution about profitability and margins, which is contributing to more tempered target prices and a tighter range of expected outcomes.
External developments in the broader health insurance space, including rebate plan changes at large competitors, keep some analysts wary about potential pressure on Oscar Health's competitive position and future pricing power.

What's in the News

House Judiciary Committee Republicans issued subpoenas to Oscar Health and seven other ACA insurers as part of an investigation into potential fraud tied to individual market premium subsidies, following the expiration of enhanced premium tax credits on January 1 (Axios).
The subpoenas are part of a broader review of the ACA individual market that also involves other large insurers such as Elevance, CVS, Centene, Kaiser Permanente, Health Care Service Corporation and Blue Shield of California, with CVS indicating it is cooperating with the inquiry (Axios).
Oscar Health issued earnings guidance for full year 2026, projecting total revenue in a range of US$18.7b to US$19.0b and Earnings from Operations between US$250 million and US$450 million.

Valuation Changes

Fair Value: revised slightly lower to about $15.40 from roughly $15.78 per share.
Discount Rate: adjusted marginally higher to about 6.98% from roughly 6.96%, implying a slightly higher required return.
Revenue Growth: modelled long term revenue growth rate moved higher to about 22.73% from roughly 9.46%.
Net Profit Margin: projected margin increased to about 3.00% from roughly 2.30%.
Future P/E: assumed forward P/E multiple moved lower to about 10.57x from roughly 17.65x, indicating a more conservative valuation multiple being applied.

0 views

Key Takeaways

Higher claims costs and evolving policy risks threaten profitability and future membership growth, despite efforts to reprice plans and leverage digital adoption trends.
Regulatory shifts and industry consolidation could inflate expenses and hinder Oscar's ability to realize anticipated technology-driven cost advantages and margin improvements.
Digital innovation, strong revenue growth, risk-adjusted pricing, strategic expansion, and financial resilience position Oscar Health for sustained profitability and market leadership.

Catalysts

About Oscar Health

Operates as a healthcare technology company in the United States.What are the underlying business or industry changes driving this perspective?

Recent market-wide increases in morbidity within the individual ACA market highlight Oscar Health's vulnerability to dynamic risk pools-heightening uncertainty in claims costs and putting pressure on the company's ability to maintain or grow net margins and future earnings, even with planned repricing actions.
Concerns over potential policy shifts-such as the expiration or non-renewal of enhanced premium tax credits-pose a risk to future membership growth and revenue, as lower subsidies could shrink Oscar's addressable market despite positive digital adoption trends.
Increasing regulatory scrutiny and program integrity efforts (e.g., Medicaid redetermination, stricter eligibility enforcement) are driving out low-utilizing members and reshaping Oscar's customer mix toward higher-cost segments, which may elevate the company's medical loss ratio and reduce profitability in the longer term.
Industry-wide acceleration toward value-based care and consolidation between payers, providers, and PBMs could exclude Oscar from favorable cost structures and preferred provider rates, limiting Oscar Health's ability to control costs and compressing operating margins.
Heightened consumer privacy concerns and the tightening of data regulation threaten Oscar's ability to fully leverage its proprietary technology and data analytics platform for differentiated underwriting and medical management, potentially slowing cost-efficiency gains and dampening margin expansion expectations.

Oscar Health Earnings and Revenue Growth

Oscar Health Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Oscar Health's revenue will grow by 22.7% annually over the next 3 years.
Analysts assume that profit margins will increase from -3.8% today to 3.0% in 3 years time.
Analysts expect earnings to reach $649.6 million (and earnings per share of $1.91) by about April 2029, up from -$443.2 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $951.9 million in earnings, and the most bearish expecting $476.5 million.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 10.6x on those 2029 earnings, up from -7.9x today. This future PE is lower than the current PE for the US Insurance industry at 11.2x.
Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 6.98%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Robust digital adoption and AI-driven efficiencies in healthcare are driving Oscar Health's operating cost reductions-such as a $60 million planned administrative cost cut in 2026-which can lead to improved net margins and set the stage for operating profitability.
Oscar Health's strong year-over-year revenue growth (29% in Q2) and consistently rising membership (28% growth, topping 2 million members) demonstrate competitive strength and sustained market demand, supporting top-line revenue expansion.
The normalization of higher market morbidity through aggressive repricing (double-digit rate increases for 2026 already refiled in nearly all markets) and productive regulator engagement increase confidence in future margin recovery and a return to positive earnings.
Strategic expansion into ICHRA and acquisitions of digital enrollment/broker platforms position Oscar to diversify revenue streams, access broader customer segments (employers as well as individuals), and gain long-term share, supporting both revenue stability and growth.
The company's substantial capital reserves ($5.4 billion in cash/investments, $579 million in excess capital at insurance subsidiaries), low leverage, and disciplined SG&A management provide ample liquidity and financial resilience, enhancing long-term earnings power and reducing solvency risk.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $15.4 for Oscar Health based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $23.0, and the most bearish reporting a price target of just $10.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $21.6 billion, earnings will come to $649.6 million, and it would be trading on a PE ratio of 10.6x, assuming you use a discount rate of 7.0%.
Given the current share price of $11.73, the analyst price target of $15.4 is 23.8% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Oscar Health?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Analysts Raise Oscar Health Price Target amid Profitability Hopes and New Healthcare Initiatives